Meta-Analysis
Copyright ©The Author(s) 2016.
World J Hepatol. Jun 28, 2016; 8(18): 770-778
Published online Jun 28, 2016. doi: 10.4254/wjh.v8.i18.770
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart summarizing study selection. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; Y90RE: Yttrium-90 radioembolization.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Forest plot of hazard ratios for overall survival after yttrium-90 radioembolization and transarterial chemoembolization. Overall estimate was non-significantly in favor of Y90RE (HR = 0.91, 0.80-1.04, P = 0.16). There was only a low level of heterogeneity among studies [χ2 = 7.32, df = 6 (P = 0.29), I2 = 18%)]. Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; HR: Hazard ratio.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Funnel plot for detection of publication bias with regard to overall survival. No evidence of publication bias was detected. HR: Hazard ratio.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Forest plot for 1-year progression-free survival after yttrium-90 radioembolization and transarterial chemoembolization. Y90RE showed a statistically significant benefit in terms of higher progression-free survival rate assessed at 1 year (OR = 1.67, 1.10-2.55, P = 0.02). There was no evidence of heterogeneity among individual studies (P = 0.66; I2 = 0%). Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; OR: Odds ratio.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Forest plot for objective response rate after yttrium-90 radioembolization and transarterial chemoembolization. Pooled analyses do not revealed a statistically significant increase in odds ratio for tumor objective responses after Y90RE with respect to TACE (OR = 1.22, 95%CI: 0.69-2.16, P = 0.50). There was, however, evidence of heterogeneity across these studies (P = 0.004; I² = 67%), mainly due to some outlier studies. Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; OR: Odds ratio.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Forest plot for serious adverse event rate after yttrium-90 radioembolization and transarterial chemoembolization. A non-significant trend in favor of Y90RE was observed (OR = 0.70, 0.38-1.30, P = 0.26), but with a high evidence of heterogeneity (I2 = 52%; P = 0.05). Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; OR: Odds ratio.